| Apr 25 |
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
|
| Apr 5 |
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
|
| Mar 29 |
Elicio Therapeutics GAAP EPS of -$6.96
|
| Mar 29 |
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
|
| Mar 18 |
Elicio Therapeutics to sell 1.03M shares $5.81 in private placement financing
|
| Mar 18 |
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
|
| Mar 6 |
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
|
| Feb 5 |
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
|
| Jan 25 |
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
|
| Jan 17 |
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
|
